|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/6/2013 9:57:25 AM
SAN DIEGO & TIVERTON, R.I.--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced publication of a review article and recommendations of an American Association of Clinical Endocrinologists (AACE) expert panel on the role of bromocriptine-QR in the management of type 2 diabetes. The panel concluded that treatment with CYCLOSET® (bromocriptine mesylate), also referred to as bromocriptine-QR, may be useful in the treatment of patients with type 2 diabetes, both early and late in the life cycle of the disease, and especially for patients with a history of cardiovascular disease or who have significant risk factors for cardiovascular disease. The article, titled The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations will appear in print form in the January/February issue of Endocrine Practice, a peer-reviewed medical journal published by AACE, and can be found in the online edition of the journal at http://aace.metapress.com/home/main.mpx.
|
|
|
|
|
|
|
|
|
|
|